Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
about
DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility studyA phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapyTreatment of advanced non small cell lung cancer.Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study.Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisSafety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.New avenues for second-line treatment of metastatic non-small-cell lung cancer.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer.
P2860
Q33418948-EC307859-574E-4281-8DC6-2A0DB2488237Q34583261-89D448C7-C963-4BF9-8349-A92BE601FB4EQ35667817-16D0DBF1-60C2-468C-823F-C4947564C15AQ35995493-AFBC4A95-0107-460D-A5BE-48E45AA224A4Q36040002-DA47230B-B81C-4759-A532-D886F0281382Q36636822-43CCF134-3F53-41FB-BC4C-4BC025C51736Q37357304-14F951C4-3023-4D0B-8A7B-4454D4CC4F6AQ37945643-426D241D-9EC9-4374-9DE6-50C0AFC7E241Q37957744-14498B2E-1015-4B8F-B114-0C87967FF87CQ38027080-1DE980D8-0928-4E41-97EF-367410CC24D9Q42984481-AB242AC2-B99D-4426-BEC5-69CB6C47E5C3Q51043526-1805FD1A-5DCF-4109-B79E-333DE36518EFQ53567790-EB231032-0BF6-44A0-9F76-66B5E5E3CEB7
P2860
Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@en
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@nl
type
label
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@en
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@nl
prefLabel
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@en
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@nl
P2093
P356
P1476
Phase II randomized trial of t ...... ed non-small cell lung cancer.
@en
P2093
Chao-Hua Chiu
Chun-Liang Lai
Chun-Ming Tsai
Gwo-Shu Wang
Reury-Perng Perng
Wei-Juin Su
Yuh-Min Chen
P304
P356
10.1093/JJCO/HYI191
P577
2005-11-22T00:00:00Z